Fast Five Quiz: HR-Positive/HER2-Negative Breast Cancer

Winston W. Tan, MD


September 14, 2021

According to the National Cancer Institute, hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) is the most common breast cancer subtype, accounting for about 68% of cases from 2014 to 2018. After traditional first-line endocrine monotherapy, the disease typically progresses despite the initial high rate of clinical benefit. Studies have aimed at optimizing treatment strategies to improve on clinical benefit beyond the traditional single-agent endocrine treatment. With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit.

What do you know about HR+/HER2- breast cancer? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.